The Role of Second Generation Sequencing Technology and Nanomedicine in the Monitoring and Treatment of Lower Extremity Deep Vein Thrombosis Susceptibility Genes

To study effect of nanomedicine on lower extremity deep vein thrombosis (LEDVT) and its correlation with susceptibility genes (SGs), preliminary nanoparticle LSA was constructed using lauric acid and stearic acid, and CTAB-HAuCL4-TEOS (CHT) was obtained using cetyltrimethyl ammonium bromide (CTAB), chloroauric acid (HAuCL4), and tetraethoxysilane (TEOS) to prepare UK-LSA-CHT by combining with urokinase (UK). 20 rabbits were grouped into UK-LSA-CHT, LSA, UK, and D0 group. Human umbilical vein endothelial cells (HUVEC) were selected for cytotoxicity test. The plasma endothelin (ET-1), interleukin 6 (IL-6), and nuclear factor κβ (NF-κβ) of the rabbits were detected with double antibody sandwich method. Expression of platelet activating factor (PAF) was detected by immumohistochemical staining. Genotype distribution was detected with the second-generation sequencing technology (SGST). The results showed that expressions of ET-1, IL-6, and NF-κβ) in UK-LSA-CHT group were lower than those in the LSA group and the UK group after 12 hours (P < 0.05). Frequency of allele G and T, and GT and TT genotype ratio of SG NOS3 rs1799983 in UK -LSA-CHT group were less than those in LSA and UK group (P < 0.05). UK-LSA-CHT group had observably lower value in PAF positive expression than LSA and UK groups (P < 0.05). In short, UK-LSA-CHT had good biocompatibility and safety and good therapeutic effect on LEDVT. N0S3 rs1799983 alleles G and T may be the key risk factors for the occurrence and development of LEDVT.